CSIR-CCMB researchers in Hyderabad have identified compounds that prevent Candida albicans from developing into invasive filaments. The approach could help control fungal infections and improve the effectiveness of existing antifungal drugs, with encouraging results in preclinical mouse models.
Published Date – 17 November 2026, 06:01 PM
Hyderabad: Researchers from Hyderabad-based Centre for Cellular and Molecular Biology (CSIR-CCMB) have unveiled a promising new strategy to combat drug-resistant fungal infections by disarming pathogens rather than killing them.
Traditional antimicrobial drugs face a growing challenge as microbial populations rapidly develop resistance to drugs. The same happens in fungal infections, where pathogens are rising but antifungal options remain scarce.
To address the challenge, a new study from Dr Sriram Varahan’s lab at CCMB focuses on Candida albicans, a common skin fungus that turns dangerous when it enters internal organs. It causes painful infections by shape-shifting from harmless round cells into long, invasive filaments that the immune system cannot control.
By targeting glycolysis, the sugar metabolism pathway that acts as a cellular switch for the physical transformation (from round cells to long invasive filaments), the team screened a library of small molecules and identified compounds that successfully block filament formation.
Interestingly, the researchers identified certain compounds that allow the fungus to survive without causing disease, highlighting pyruvate kinase as a vital metabolic node for controlling fungal behaviour.
Moreover, in the study, the researchers reported that one of the lead compounds increased pathogen sensitivity to conventional drugs like fluconazole and amphotericin B, and significantly improved survival in preclinical mouse models. Published in ACS Infectious Diseases, the research was conducted in collaboration with BRIC-THSTI scientists.

